[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510693":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":43,"responsibleParty":65,"collaborators":69,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":26,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":26,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"UConn Health","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group (standard care)","PLACEBO_COMPARATOR","1 cc gel foam powder mixed with thrombin",[13],"Drug: Gel-Flow NT",{"label":15,"type":16,"description":17,"interventionNames":18},"Test group (standard care + study intervention)","EXPERIMENTAL","1 cc of gel foam powder mixed with thrombin and 80mg Depo-Medrol",[19,13],"Drug: Depo-Medrol",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Depo-Medrol","steroid",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Gel-Flow NT","hemostatic agent",[9,15],[32],{"name":33,"affiliation":5,"role":34},"Hardeep Singh, M.D.","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Hardeep Singh, MD","CONTACT","860-679-6883","uconnorthopaedics@uchc.edu",{"name":42,"role":38,"phone":39,"phoneExt":26,"email":40},"Study Coordinator",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Farmington","Connecticut","06030","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-72.83204,41.71982,{"lat":55,"lon":54},[58,59,60,63],{"name":42,"role":38,"phone":26,"phoneExt":26,"email":40},{"name":33,"role":34,"phone":26,"phoneExt":26,"email":26},{"name":61,"role":62,"phone":26,"phoneExt":26,"email":26},"Isaac Moss, M.D., C.M., M.A.Sc., FRCSC","SUB_INVESTIGATOR",{"name":64,"role":62,"phone":26,"phoneExt":26,"email":26},"Scott Mallozzi, M.D.",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Hardeep Singh","Assistant Professor of Orthopedic Surgery",[70],{"name":71,"class":6},"Society for Minimally Invasive Spine Surgery","100510693","phase-4-depo-medrol-on-psoas-after-llif-100510693",false,"NCT05929755","Depo-Medrol on Psoas After LLIF","Effect of Depo-Medrol Application on the Psoas Muscle After Transpsoas LLIF on Post-operative Hip Flexor Weakness, Thigh Pain and Numbness","Inclusion Criteria:\n\n* Patients from the practices of Drs. Singh, Mallozzi, Moss\n* Transpsoas (PTP or LTP) lateral lumbar interbody fusion (LLIF) 1-3 disc levels with posterior instrumentation (Open or MIS) with or without laminectomy, must include L3-4 and\u002For L4-5\n* Patients who agree to be a part of the study\n* Patients with lumbar disc degeneration\n* Patients between ages of 18 and 75\n\nExclusion Criteria:\n\n* Scoliosis \\>10°\n* Spondylolisthesis \\>Grade 1\n* Flatback deformity\n* Patients with insulin dependent diabetes\n* Patients with \\>3 levels of fusion\n* Alternative interbodies\n* Chronic oral steroid users\n* Patients with allergy\u002Fintolerance to depo-medrol or other steroids\n* Patients requiring bilateral transpsoas approaches\n* Patients with ipsilateral symptomatic hip pathology\n* Revision fusion procedures\n* Cases involving trauma, tumor, or infection\n* Patient's not capable of providing consent themselves\n* Non-fluent English speakers (for consenting reasons)\n* Patients who are lost to follow-up before the two year follow up period","ALL","18 Years","75 Years",{"count":83,"type":84},80,"ESTIMATED","INTERVENTIONAL",[87],"PHASE4","The goal of this study is to determine the effects of a corticosteroid administered to the psoas muscle following a transpsoas lateral lumbar interbody fusion (LLIF) on postoperative hip flexor weakness and thigh pain and numbness.",[90,91,92,93],"Muscle Weakness","Pain, Postoperative","Paresthesia","Pain, Muscle",[95,96,23,97,98,99,100,101,102],"lateral lumbar interbody fusion","LLIF","corticosteroid","lumbar spine","psoas muscle","postoperative hip flexor weakness","postoperative thigh pain","postoperative thigh numbness","2025-07-18",{"date":105,"type":106},"2025-07-24","ACTUAL",{"date":108,"type":106},"2023-05-12",{"date":110,"type":84},"2027-05",{"name":67,"class":6},1]